tbuckley/cabot-search huggingface dataset:
Model-based evaluation of the efficacy and safety of nivolumab once every 4 weeks across multiple tumor types
Authors: X. Zhao, J. Shen, V. Ivaturi, M. Gopalakrishnan, Y. Feng, B.J. Schmidt, P. Statkevich, V. Goodman, J. Gobburu, A. Bello, A. Roy, S. Agrawal
Journal: Annals of Oncology (2020)

Nivolumab 480 mg every 4 weeks (Q4W) is approved in the European Union, United States, and several other markets across multiple tumor types. Its approval was supported by quantitative efficacy/safety analyses bridging to 3 mg/kg every 2 weeks (Q2W).The benefit-risk profile of nivolumab 480 mg Q4W relative to 3 mg/kg Q2W was evaluated using population pharmacokinetic modeling and exposure-response (E-R) analyses for safety and efficacy. Pharmacokinetic exposures were predicted for 3203 patients with melanoma, non-small-cell lung cancer (NSCLC), renal cell carcinoma (RCC), squamous cell carcinoma of the head and neck, urothelial carcinoma, or classical Hodgkin lymphoma. Quantitative models analyzed E-R to predict 480-mg Q4W safety across all indications and efficacy for melanoma, NSCLC, and RCC. Intratumoral receptor occupancy (RO) was predicted for parameters representing different tumor types.Time-averaged concentrations for 480 mg Q4W versus 3 mg/kg Q2W were higher during the first 28 days (26.8%) and similar at steady state (5.2%). The maximum concentration (Cmax) after the first dose was higher (110.4%), and the trough concentration at day 28 was lower (-22.1%) with 480 mg Q4W versus 3 mg/kg Q2W. The Cmax achieved with 480 mg Q4W was lower than the previously established safe dose of 10 mg/kg Q2W. The probability of adverse events for key safety end points was similar for 480 mg Q4W and 3 mg/kg Q2W. The predicted overall survival and objective response rates with 480 mg Q4W were comparable to 3 mg/kg Q2W. The predicted high intratumoral RO provided additional evidence to support 480 mg Q4W across tumor types.The benefit-risk profile for nivolumab 480 mg Q4W was predicted to be similar to that of 3 mg/kg Q2W across tumor types while providing a convenient and flexible option for patients and their caregivers.
A Three-Step Strategy of Induction Chemotherapy, Chemo-Radiotherapy and Surgery in Locally advanced Pancreatic Cancer (LAPC). A Single Institutional Experience
Authors: O.E. Carranza Rua, E. Arevalo, J.P. Fusco, E. Castanon Alvarez, L. Zubiri, J.A. Gonzalez, L. Arbea, F. Pardo, S. Martin Algarra, J. Rodriguez
Journal: Annals of Oncology (2012)
O-0018 Efficacy and Safety of Bevacizumab in Metastatic Colorectal Cancer: Overall and Subgroup Analyses of Pooled Data from Randomized Controlled Trials
Authors: Herbert Hurwitz, Niall Tebbutt, Fairooz Kabbinavar, Bruce Giantonio, Zhong-Zhen Guan, Lada Mitchell, Daniel Waterkamp, Josep Tabernero
Journal: Annals of Oncology (2012)
P-0093 Us Treatment Patterns and Costs for Patients with Hepatocellular Cancer who Have Received Sorafenib as First-Line Therapy
Authors: Michael Stokes, Astra Liepa, Chien-Chia Chuang, Yulia D'yachkova, Alan Wang, Luke Boulanger, Craig Hunter, Jonathan Schwartz
Journal: Annals of Oncology (2012)
First-Line Gefitinib Treatment for Elderly Patients with Non-Small Cell Lung Cancer Harboring EGFR Mutation: Multicenter Phase II Trial CJLSG0901
Authors: K. Takahashi, H. Saito, M. Yamamoto, E. Kojima, T. Yokoyama, Y. Sugino, T. Kimura, T. Ogasawara, R. Suzuki, Y. Hasegawa
Journal: Annals of Oncology (2012)
The <i>MUC5B</i> promoter risk allele for idiopathic pulmonary fibrosis predisposes to asbestosis
Authors: Mark G.J.P. Platenburg, Ivo A. Wiertz, Joanne J. van der Vis, Bruno Crestani, Raphael Borie, Philippe Dieude, Caroline Kannengiesser, Jacobus A. Burgers, Jan C. Grutters, Coline H.M. van Moorsel
Journal: European Respiratory Journal (2020)

Asbestosis is a fibrosing interstitial pneumonitis, which can develop following occupational asbestos exposure and a lengthy latency period [1]. Even after strict regulations on the asbestos industry, an estimated 3400 individuals worldwide died as a consequence of asbestosis in 2017 [2]. The minor allele of MUC5B rs35705950 predisposes to asbestosis, but has no effect on survival <http://bit.ly/382gPBM>
P-0287 Prospective Trial of Synchronous Capecitabine, Radiotherapy and Bevacizumab for Locally Advanced Rectal Cancer (Crab)
Authors: Vaneja Velenik, Janja Ocvirk, Maja Mušicˇ, Bracˇko Matej, Franc Anderluh, Irena Oblak, Ibrahim Edhemovic´, Erik Brecelj, Mateja Kropivnik, Mirko Omejc
Journal: Annals of Oncology (2012)
Phase I trial of everolimus, gemcitabine and cisplatin for patients with solid tumors refractory to standard therapy.
Authors: Brian Addis Costello, Yingwei Qi, Mitesh J. Borad, George P. Kim, Donald W. Northfelt, Charles Erlichman, Steven R. Alberts
Journal: Journal of Clinical Oncology (2012)

e13052 Background: The combination of GEM and CDDP has shown activity in a variety of cancers, including biliary tract/gallbladder. Preclinical testing shows a potential benefit to the addition of EV. Methods: Using a standard 3+3 design, the MTDs of GEM + EV (Cohort I) and GEM + CDDP + EV (Cohort II) were determined as shown in the table. The MTD was defined as the dose level below the lowest dose that induces a DLT in at least one-third of pts. At the MTD of Cohort II, 10 patients were enrolled with biliary tract/gallbladder cancer (Cohort III). A weekly CBC was obtained. Assessments occurred every 3 weeks and imaging for response at every other cycle. Results: In Cohort I (N=12), no DLT occurred at dose level 0, and in dose level 1, grade 3 thrombocytopenia was found in 2 of 6 pts. The MTD for Cohort I was determined to be dose level 0. Responses were seen in 3 pts: 2 CRs (primary peritoneal, pancreatic) and 1 PR (breast). In Cohort II (N=15) DLTs at dose level 0 were neutropenia and thrombocytopenia in 2 of 3 pts and at dose level -1, thrombocytopenia in 2 of 6 pts. At dose level -2, 1 of 6 pts experienced a DLT (grade 3 thrombocytopenia), establishing this dose level as the MTD. Responses were seen in 2 pts, both PRs (ampullary, pheochromocytoma). All 10 pts have been enrolled in Cohort III with 2 DLTs (neutropenia and thrombocytopenia). Stable disease seen in 5 of 7 evaluable pts. Conclusions: Gem + EV was well tolerated at dose level 0, though dose escalation was limited by thrombocytopenia. GEM + CDDP + EV had DLTs of neutropenia and thrombocytopenia leading to the MTD of dose level of -2. Cohort III is fully accrued and the 2 DLTs are hematologic. [Table: see text]
Metastatic Uveal Melanoma: A 22 Years Single Center Experience
Authors: S. Valpione, C. Aliberti, J. Pigozzo, E. Midena, R. Parrozzani, S. Stragliotto, P.L. Pilati, L.G. Campana, V. Chiarion Sileni
Journal: Annals of Oncology (2012)
A Step Toward Standardizing Clinical Trials of Actinic Keratosis
Authors: Aditya K. Gupta, George Martin, Helen J Renaud
Journal: JAMA Dermatology (2020)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Dermatology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Dermatology journal
Adjuvant MFOLFOX6 in the Treatment of Elderly Colon Cancer Patients
Authors: J. Godinho Bexiga, F. Carneiro, D.S. Marques, N. Sousa, A. Raimundo, M. Machado, P. Ferreira, C. Faustino, M. Fragoso
Journal: Annals of Oncology (2012)
Depression and post-traumatic stress during major social unrest in Hong Kong: a 10-year prospective cohort study
Authors: Michael Y Ni, Xiaoxin I Yao, Kathy S M Leung, Cynthia Yau, Candi M C Leung, Phyllis Lun, Francis P Flores, Wing Chung Chang, Benjamin J Cowling, Gabriel M Leung
Journal: The Lancet (2020)
A Multicenter, Randomized Phase II Study of V (Vinorelbine)/C (Cisplatin)/B (Bevacizumab) Followed by D (Docetaxel)/G (Gemcitabine)/B Versus D/ C /B as a First-Line Therapy for Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
Authors: A. Kotsakis, E. Kontopodis, N. Vardakis, K. Kalbakis, N. Kentepozidis, A. Xyrafas, C. Christofilakis, D. Mavroudis, V. Georgoulias
Journal: Annals of Oncology (2012)
SR-BI as a target of natural products and its significance in cancer
Authors: Dongdong Wang, Jiansheng Huang, Ting Gui, Yaxin Yang, Tingting Feng, Nikolay T. Tzvetkov, Tao Xu, Zhibo Gai, Ying Zhou, Jingjie Zhang, Atanas G. Atanasov
Journal: Seminars in Cancer Biology (2020)
P-0243 CLinical Outcomes of Bevacizumab used in Community Oncology Metastatic Colorectal Cancer (MCRC) Patients with Confirmed Kras-Status
Authors: Thomas Cartwright, Yeun Mi Yim, Elaine Yu, Dhanda Rahul, Wan-Yu Tseng, Michael Forsyth, William Lopez
Journal: Annals of Oncology (2012)
Evaluating the Placebo Status of Nebulized Normal Saline in Patients With Acute Viral Bronchiolitis
Authors: Samantha A. House, Anne M. Gadomski, Shawn L. Ralston
Journal: JAMA Pediatrics (2020)

In therapeutic trials for acute viral bronchiolitis, consistent clinical improvement in groups that received nebulized normal saline (NS) as placebo raises the question of whether nebulized NS acts as a treatment rather than a placebo.To measure the short-term association of nebulized NS with physiologic measures of respiratory status in children with bronchiolitis by analyzing the changes in these measures between the use of nebulized NS and the use of other placebos and the changes before and after nebulized NS treatment.MEDLINE and Scopus were searched through March 2019, as were bibliographies of included studies and relevant systematic reviews, for randomized clinical trials evaluating nebulized therapies in bronchiolitis.Randomized clinical trials comparing children 2 years or younger with bronchiolitis who were treated with nebulized NS were included. Studies enrolling a treatment group receiving an alternative placebo were included for comparison of NS with other placebos.Data abstraction was performed per PRISMA guidelines. Fixed- and random-effects, variance-weighted meta-analytic models were used.Pooled estimates of the association with respiratory scores, respiratory rates, and oxygen saturation within 60 minutes of treatment were generated for nebulized NS vs another placebo and for change before and after receiving nebulized NS.A total of 29 studies including 1583 patients were included. Standardized mean differences in respiratory scores for nebulized NS vs other placebo (3 studies) favored nebulized NS by -0.9 points (95% CI, -1.2 to -0.6 points) at 60 minutes after treatment (P < .001). There were no differences in respiratory rate or oxygen saturation comparing nebulized NS with other placebo. The standardized mean difference in respiratory score (25 studies) after nebulized NS was -0.7 (95% CI, -0.7 to -0.6; I2 = 62%). The weighted mean difference in respiratory scores using a consistent scale (13 studies) after nebulized NS was -1.6 points (95% CI, -1.9 to -1.3 points; I2 = 72%). The weighted mean difference in respiratory rate (17 studies) after nebulized NS was -5.5 breaths per minute (95% CI, -6.3 to -4.6 breaths per minute; I2 = 24%). The weighted mean difference in oxygen saturation (23 studies) after nebulized NS was -0.4% (95% CI, -0.6% to -0.2%; I2 = 79%).Nebulized NS may be an active treatment for acute viral bronchiolitis. Further evaluation should occur to establish whether it is a true placebo.
Improving Quantum Yield of a NIR‐II Dye by Phenylazo Group
Authors: Ling'e Zhang, Changren Liu, Sensen Zhou, Ruonan Wang, Quli Fan, Dongfang Liu, Wei Wu, Xiqun Jiang
Journal: Advanced Healthcare Materials (2020)

Understanding structure-fluorescence correlation is very helpful for the design of fluorescent probes. In this paper, a donor-acceptor-donor (D-A-D) type NIR-II fluorophore with benzobisthiadiazole as the acceptor and triphenyl amine as the donor, and its three derivatives bearing respectively amino, tert-butyloxycarbonyl amino and phenylazo groups in donor moieties, are synthesized. Their electronic structures and optical properties are investigated via theoretical and experimental studies. It is found that all the three types of substituents significantly influence its fluorescent properties and the phenylazo groups dramatically enhance its quantum yield (QY). To achieve biological applications and maintain high QY in aqueous environments, the phenylazo-containing fluorophore is encapsulated in polystyrene-co-poly(ethylene glycol) micelles. The obtained fluorescent micelles have a QY of ≈3.51% in 1000-1500 nm in aqueous medium that is among the highest of the organic NIR-II probes reported so far for biological imaging. The high QY enables the in vivo imaging of the micelle-administered mice to be conducted with high speed and quality. As an application example, ultrafast NIR-II imaging of intravenously injected mice is performed and used to determine their cardiac cycle and heart rate. The micelles also significantly accumulate in tumors after tail-vein injection and exhibit great application potentials in tumor detection.
Deficiency of Circulating Monocytes Ameliorates the Progression of Myxomatous Valve Degeneration in Marfan Syndrome
Authors: Andrew J. Kim, Na Xu, Kazuhiro Umeyama, Alexia Hulin, Sithara Raju Ponny, Ronald J. Vagnozzi, Ellis A. Green, Paul Hanson, Bruce M. McManus, Hiroshi Nagashima, Katherine E. Yutzey
Journal: Circulation (2020)

Background: Myxomatous valve degeneration (MVD) involves the progressive thickening and degeneration of the heart valves, leading to valve prolapse, regurgitant blood flow, and impaired cardiac function. Leukocytes composed primarily of macrophages have recently been detected in myxomatous valves, but the timing of the presence and the contributions of these cells in MVD progression are not known. Methods: We examined MVD progression, macrophages, and the valve microenvironment in the context of Marfan syndrome (MFS) using mitral valves from MFS mice ( Fbn1 C1039G/+ ), gene-edited MFS pigs ( FBN1 Glu433AsnfsX98/+ ), and patients with MFS. Additional histological and transcriptomic evaluation was performed by using nonsyndromic human and canine myxomatous valves, respectively. Macrophage ontogeny was determined using MFS mice transplanted with mTomato+ bone marrow or MFS mice harboring RFP (red fluorescent protein)–tagged C-C chemokine receptor type 2 (CCR2) monocytes. Mice deficient in recruited macrophages ( Fbn1 C1039G/+ ;Ccr2 RFP/RFP ) were generated to determine the requirements of recruited macrophages to MVD progression. Results: MFS mice recapitulated histopathological features of myxomatous valve disease by 2 months of age, including mitral valve thickening, increased leaflet cellularity, and extracellular matrix abnormalities characterized by proteoglycan accumulation and collagen fragmentation. Diseased mitral valves of MFS mice concurrently exhibited a marked increase of infiltrating (MHCII+, CCR2+) and resident macrophages (CD206+, CCR2–), along with increased chemokine activity and inflammatory extracellular matrix modification. Likewise, mitral valve specimens obtained from gene-edited MFS pigs and human patients with MFS exhibited increased monocytes and macrophages (CD14+, CD64+, CD68+, CD163+) detected by immunofluorescence. In addition, comparative transcriptomic evaluation of both genetic (MFS mice) and acquired forms of MVD (humans and dogs) unveiled a shared upregulated inflammatory response in diseased valves. Remarkably, the deficiency of monocytes was protective against MVD progression, resulting in a significant reduction of MHCII macrophages, minimal leaflet thickening, and preserved mitral valve integrity. Conclusions: All together, our results suggest sterile inflammation as a novel paradigm to disease progression, and we identify, for the first time, monocytes as a viable candidate for targeted therapy in MVD.
Morphine and Cardiovascular Outcomes Among Patients With Non-ST-Segment Elevation Acute Coronary Syndromes Undergoing Coronary Angiography
Authors: Remo H.M. Furtado, José C. Nicolau, Jianping Guo, Kyungah Im, Jennifer A. White, Marc S. Sabatine, L. Kristin Newby, Robert P. Giugliano
Journal: Journal of the American College of Cardiology (2020)
Impact of Multifocal or Multicentric Disease on Surgical, Locoregional, and Distant Survival After Neoadjuvant Chemotherapy in 3562 Breast Cancer Patients
Authors: B. Ataseven, J.U. Blohmer, C. Denkert, B. Gerber, J. Heil, T. Kühn, S. Kümmel, M. Rezai, S. Loibl, G. von Minckwitz
Journal: Annals of Oncology (2012)
Metabolic Reprogramming in Cancer Is Induced to Increase Proton Production
Authors: Huiyan Sun, Yi Zhou, Michael Francis Skaro, Yiran Wu, Zexing Qu, Fenglou Mao, Suwen Zhao, Ying Xu
Journal: Cancer Research (2020)

Abstract Considerable metabolic reprogramming has been observed in a conserved manner across multiple cancer types, but their true causes remain elusive. We present an analysis of around 50 such reprogrammed metabolisms (RM) including the Warburg effect, nucleotide de novo synthesis, and sialic acid biosynthesis in cancer. Analyses of the biochemical reactions conducted by these RMs, coupled with gene expression data of their catalyzing enzymes, in 7,011 tissues of 14 cancer types, revealed that all RMs produce more H+ than their original metabolisms. These data strongly support a model that these RMs are induced or selected to neutralize a persistent intracellular alkaline stress due to chronic inflammation and local iron overload. To sustain these RMs for survival, cells must find metabolic exits for the nonproton products of these RMs in a continuous manner, some of which pose major challenges, such as nucleotides and sialic acids, because they are electrically charged. This analysis strongly suggests that continuous cell division and other cancerous behaviors are ways for the affected cells to remove such products in a timely and sustained manner. As supporting evidence, this model can offer simple and natural explanations to a range of long-standing open questions in cancer research including the cause of the Warburg effect. Significance: Inhibiting acidifying metabolic reprogramming could be a novel strategy for treating cancer.
Induction Chemotherapy with Docetaxel, Cisplatin and 5-Fluorouracil Followed by Radiotherapy with Cetuximab for Locally Advanced Squamous Cell Carcinoma of the Head and Neck
Authors: F. Keil, E. Selzer, A. Berghold, K. Kapp, A. De Vries, R. Greil, S. Reinisch, W. Anderhuber, M. Burian, G.V. Kornek
Journal: Annals of Oncology (2012)
The patient's point of view
Authors: Paola Mosconi, Ferrucio Aloe, Giovanna Bruno, Paolo Nitti, Nadia Crotti, Cristiana Rossi, Ada Burrone, Giovanna Fromento, MariaElisabetta Gangale, RobertaCiurekgian Scandurra, Margherita Serrano, Rosanna Sorrentino, Lidia Brambilla, Mariella Cagnetta, Irvana D'Errico, Maria De Bellis, Adriana Carneglia, Vienna Falcone, MariaCristina Fossati, AnnaMancuso Galli, Ornella Lepore, Antonia Magarelli, Lina Mandelli, Luciana Marini, Teresa Milella, Vincenza Mori, Adriana Peschiulli, MariaPia Polenghi, Maria Trisciuoglio, Mariangela Villa, Luisella Ferrari, Giovanna Nencini, Stefano Gastaldi, Luigi Valera, Salvo Catania, MariaAntonietta Nosenzo
Journal: Annals of Oncology (1995)
Preclinical evaluation of patient-derived cells shows promise for Parkinson’s disease
Authors: Jun Takahashi
Journal: Journal of Clinical Investigation (2020)

Parkinson's disease (PD) is a neurodegenerative disease caused by the progressive loss of dopaminergic (DA) neurons in the midbrain projecting to the striatum, which leads to motor dysfunctions, such as bradykinesia (slowed movement), rigidity, and tremors. To replace the lost cells, the transplantation of DA neurons derived from embryonic stem cells or induced pluripotent stem cells (iPSCs) has been considered. In this issue of the JCI, Song et al. report on their development of an iPSC induction and differentiation protocol that can promote the realization of autologous transplantation to treat PD patients with their own cells.
Impact of Diabetes and Hyperglycemia on Survival in Advanced Breast Cancer Patients
Authors: R.J. Shaw Dulin, C. Villarreal-Garza, F. Lara, L. Bacon, D. Rivera, A.D. Rivera Salceda, L. Urzua, L. Herrera, C. Aguila, J.E. Bargallo-Rocha
Journal: Annals of Oncology (2012)
カペシタビンによる手足症候群の予防における,尿素/乳酸ベースの外用角質溶解剤の有効性を明らかにするプラセボ比較対照試験:米国の北中部癌治療グループ (NCCTG)の試験N05C5 | 文献情報 | J-GLOBAL 科学技術総合リンクセンター
Authors: L Wolf Sherry, Qin Rui, P Menon Smitha, Rowland Kendrith M., Thomas Sachdev, Delaune Robert, Christian Diana, Pajon Eduardo R., V Satele Daniel, L Berenberg Jeffrey, L Loprinzi Charles
Journal: Journal of Clinical Oncology (2010)
P-0142 Oxaliplatin-Based Regimens: Evaluating Neurotoxicity of Weekly Versus Bi/Tri Weekly Doses of Oxaliplatin in Git Cancers
Authors: Noha Abbas, Mennatallah ElMeligie, Omar Abd El Rhman, Raafat Ragaie, Hamdy Azim
Journal: Annals of Oncology (2012)
A Multicenter Phase II Study of Neoadjuvant Chemotherapy (NAC) Combined with Docetaxel, Cisplatin and S-1 (DCS) for Locally advanced Gastric Cancer (AGC)
Authors: N. Fukushima, A. Nashimoto, S. Fushida, Y. Kawachi, S. Kuwabara, N. Musha
Journal: Annals of Oncology (2012)
Final Analysis of Phase I and Pharmacokinetics/Pharmacodynamics (PK/PD) Study of RO5126766, A First-in-Class Dual Raf/Mek Inhibitor, in Japanese Patients With Advanced Solid Tumors
Authors: K. Honda, N. Yamamoto, H. Nokihara, Y. Tamura, H. Asahina, Y. Yamada, S. Suzuki, N. Yamazaki, T. Tamura
Journal: Annals of Oncology (2012)
Synergy Between the KEAP1/NRF2 and PI3K Pathways Drives Non-Small Cell Lung Cancer with an Altered Metabolism
Authors: S Best, D Desouza, A Kersbergen, A Policheni, S Dayalan, D Tull, V Rathi, D Gray, M Ritchie, M Mcconyille, K Sutherland
Journal: Journal of Thoracic Oncology (2018)
Continued Sunitinib Treatment After Progressive Disease (PD) in a Worldwide Treatment-Use Trial of Patients (PTS) With Gastrointestinal Stromal Tumor (GIST)
Authors: P. Reichardt, Y. Kang, P. Rutkowski, J. Schuette, L.S. Rosen, B. Seddon, S. Yalcin, L. Chen, K. Fly, G. Demetri
Journal: Annals of Oncology (2012)
lncRNA Sensing of a Viral Suppressor of RNAi Activates Non-canonical Innate Immune Signaling in Drosophila
Authors: Liqin Zhang, Wen Xu, Xinlei Gao, Wenjie Li, Shuishui Qi, Dongyang Guo, Olugbenga Emmanuel Ajayi, Shou-Wei Ding, Qingfa Wu
Journal: Cell Host & Microbe (2020)
Efficacy and Safety of the Hedgehog Pathway Inhibitor Vismodegib in Patients with Advanced Basal Cell Carcinoma (BCC): 12-Month Erivance BCC Study Update
Authors: A. Sekulic, M.R. Migden, A. Oro, K. Lewis, J.D. Hainsworth, S. Yoo, L. Dirix, J. Hou, H. Yue, A. Hauschild
Journal: Annals of Oncology (2012)